1-(N-tert-butoxycarbonyl-D-Tic-4-Cl-D-Phe)-4-phenylpiperazine | 668980-39-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-(N-tert-butoxycarbonyl-D-Tic-4-Cl-D-Phe)-4-phenylpiperazine
• 英文别名: 1-[(N-tert-butoxycarbonyl-D-1,2,3,4-tetrahydroisoquinoline-3-carbonyl)-4-chloro-D-phenylalanyl]-4-phenylpiperazine；Boc-D-Tic-D-Phe(4-Cl)-piperazino(4-Ph)；tert-butyl (3R)-3-[[(2R)-3-(4-chlorophenyl)-1-oxo-1-(4-phenylpiperazin-1-yl)propan-2-yl]carbamoyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate
• CAS: 668980-39-0
• 化学式: C₃₄H₃₉ClN₄O₄
• 分子量: 603.161
• InChiKey: JYXJXPXBNVMQAE-LOYHVIPDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  43
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  82.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(N-tert-butoxycarbonyl-D-Tic-4-Cl-D-Phe)-4-phenylpiperazine 在 双氧水 、 溶剂黄146 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 1-[(D-1,2,3,4-tetrahydroisoquinoline-3-carbonyl)-4-chloro-D-phenylalanyl]-4-oxy-4-phenylpiperazine ditrifluoroacetate
  参考文献：
  名称：

  新的取代哌嗪作为黑皮质素受体的配体。与“ THIQ”的X射线结构相关。

  摘要：

  合成了一系列黑皮质素4受体（MC4R）特异性小分子激动剂“ THIQ”的哌嗪类似物，并在结构和药理上进行了表征。首先，准备了一些缺少三唑部分的THIQ仿制品。合成包括4-苯基哌嗪或4-环己基哌嗪的酰化。在两种情况下，叔胺官能团被相应的N-氧化物代替。为了获得更复杂的结构，通过用N，N-双（2-氯乙基）苄胺烷基化环己烷衍生的氨基醇的伯氨基，形成4-取代的哌嗪环。首先用甲磺酰氯活化中间体的羟基，然后将原位形成的磺酸酯与1,2,4-三唑的钠盐引入反应中。在一种情况下（即，制备23c）在环己烷环的碳上引入1,2,4-三唑部分。另外，该中间体含有通过其氮原子与反应中心附近的环己烷环碳连接的哌嗪部分。如本文的NMR和X射线研究中所确定的，该取代在保留1，2-二取代的环己烷的初始反式构型的情况下进行。为了获得23c的纯对映异构体，将其前体21c在Chirobiotic V柱上进行手性色谱法。将获得的衍生

  DOI：

  10.1021/jm0311285
• 作为产物：
  描述：

  D-对氯苯丙氨酸甲酯 在 4-二甲氨基吡啶 、 sodium hydroxide 、 N-羟基-7-氮杂苯并三氮唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-(N-tert-butoxycarbonyl-D-Tic-4-Cl-D-Phe)-4-phenylpiperazine
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of Novel Arylpiperazines as Potent and Selective Agonists of the Melanocortin Subtype-4 Receptor

  摘要：

  The melanocortin receptors have been implicated as potential targets for a number of important therapeutic indications, including inflammation, sexual dysfunction, and obesity. We identified compound 1, an arylpiperazine attached to the dipeptide H-D-Tic-D-p-Cl-Phe-OH, as a novel melanocortin subtype-4 receptor (MC4R) agonist through iterative directed screening of nonpeptidyl G-protein-coupled receptor biased libraries. Structure-activity relationship (SAR) studies demonstrated that substitutions at the ortho position of the aryl ring improved binding and functional potency. For example, the o-isopropyl-substituted compound 29 (K-i = 720 nM) possessed 9-fold better binding affinity compared to the unsubstituted aryl ring (K-i = 6600 nM). Sulfonamide 39 (K-i = 220 nM) fills this space with a polar substituent, resulting in a further 2-fold improvement in binding affinity. The most potent compounds such as the diethylamine 44 (K-i = 60 nM) contain a basic group at this position. Basic heterocycles such as the imidazole 50 (K-i = 110 nM) were similarly effective. We also demonstrated good oral bioavailability for sulfonamide 39.

  DOI：

  10.1021/jm0304109

文献信息

• Synthesis and Structure−Activity Relationships of Novel Arylpiperazines as Potent and Selective Agonists of the Melanocortin Subtype-4 Receptor
  作者：Timothy I. Richardson、Paul L. Ornstein、Karin Briner、Matthew J. Fisher、Ryan T. Backer、C. Kelly Biggers、Michael P. Clay、Paul J. Emmerson、Larry W. Hertel、Hansen M. Hsiung、Saba Husain、Steven D. Kahl、Jonathan A. Lee、Terry D. Lindstrom、Michael J. Martinelli、John P. Mayer、Jeffery T. Mullaney、Thomas P. O'Brien、Joseph M. Pawlak、Kevin D. Revell、Jikesh Shah、John M. Zgombick、R. Jason Herr、Alex Melekhov、Peter B. Sampson、Chi-Hsin R. King

  DOI：10.1021/jm0304109

  日期：2004.1.1

  The melanocortin receptors have been implicated as potential targets for a number of important therapeutic indications, including inflammation, sexual dysfunction, and obesity. We identified compound 1, an arylpiperazine attached to the dipeptide H-D-Tic-D-p-Cl-Phe-OH, as a novel melanocortin subtype-4 receptor (MC4R) agonist through iterative directed screening of nonpeptidyl G-protein-coupled receptor biased libraries. Structure-activity relationship (SAR) studies demonstrated that substitutions at the ortho position of the aryl ring improved binding and functional potency. For example, the o-isopropyl-substituted compound 29 (K-i = 720 nM) possessed 9-fold better binding affinity compared to the unsubstituted aryl ring (K-i = 6600 nM). Sulfonamide 39 (K-i = 220 nM) fills this space with a polar substituent, resulting in a further 2-fold improvement in binding affinity. The most potent compounds such as the diethylamine 44 (K-i = 60 nM) contain a basic group at this position. Basic heterocycles such as the imidazole 50 (K-i = 110 nM) were similarly effective. We also demonstrated good oral bioavailability for sulfonamide 39.
• New Substituted Piperazines as Ligands for Melanocortin Receptors. Correlation to the X-ray Structure of “THIQ”
  作者：Felikss Mutulis、Sviatlana Yahorava、Ilze Mutule、Aleh Yahorau、Edvards Liepinsh、Sergei Kopantshuk、Santa Veiksina、Kaspars Tars、Sergey Belyakov、Anatoly Mishnev、Ago Rinken、Jarl E. S. Wikberg

  DOI：10.1021/jm0311285

  日期：2004.8.1

  characterized structurally and pharmacologically. First, several THIQ imitations lacking the triazole moiety were prepared. Syntheses included acylation of 4-phenylpiperazine or 4-cyclohexylpiperazine. In two cases the tertiary amine function was replaced by the corresponding N-oxide. To obtain more complex structures, a 4-substituted piperazine ring was formed by alkylation of the primary amino group

  合成了一系列黑皮质素4受体（MC4R）特异性小分子激动剂“ THIQ”的哌嗪类似物，并在结构和药理上进行了表征。首先，准备了一些缺少三唑部分的THIQ仿制品。合成包括4-苯基哌嗪或4-环己基哌嗪的酰化。在两种情况下，叔胺官能团被相应的N-氧化物代替。为了获得更复杂的结构，通过用N，N-双（2-氯乙基）苄胺烷基化环己烷衍生的氨基醇的伯氨基，形成4-取代的哌嗪环。首先用甲磺酰氯活化中间体的羟基，然后将原位形成的磺酸酯与1,2,4-三唑的钠盐引入反应中。在一种情况下（即，制备23c）在环己烷环的碳上引入1,2,4-三唑部分。另外，该中间体含有通过其氮原子与反应中心附近的环己烷环碳连接的哌嗪部分。如本文的NMR和X射线研究中所确定的，该取代在保留1，2-二取代的环己烷的初始反式构型的情况下进行。为了获得23c的纯对映异构体，将其前体21c在Chirobiotic V柱上进行手性色谱法。将获得的衍生